SPY334.89+2.52 0.76%
DIA277.50+3.08 1.12%
IXIC11,167.51+82.26 0.74%

RBC Capital Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $200

RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and lowers the price target from $215 to $200.

Benzinga · 12/23/2019 13:37

RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and lowers the price target from $215 to $200.